New bioRxiv paper showcases:
- Tumor-informed ctDNA detection down to one-in-ten million (10-7), which extends well beyond the limits of currently available clinical minimal residual disease (MRD) assays
- Superior double-stranded DNA (dsDNA) recovery rates versus other technologies, reducing sequencing requirements by 10- to 100-fold to achieve ultrasensitive detection levels and enabling a cost-effective whole-genome approach
- High efficiency and simple WGS workflow, yielding greater than 20x coverage per ng of cfDNA, reducing the amount of input material required for MRD and other liquid biopsy applications
- New highly sensitive approach to tumor-informed MRD as well as tumor-naive MRD and monitoring settings, where matched tumor tissue is not available
FREMONT, Calif., Aug. 14, 2025 -- Ultima Genomics, a developer and manufacturer of an innovative ultra-high throughput sequencing architecture, announced a new publication, made available today in bioRxiv, showing the ultra-sensitive single-nucleotide variant (SNV) detection capabilities of its ppmSeq™ technology, with error rates down to 8 x 10-8. Led by researchers from the Landau Lab at Weill Cornell Medicine and the New York Genome Center, this pre-print also demonstrates ctDNA detection limits for ppmSeq which significantly extends beyond the limits of currently available MRD assays, while utilizing a simple whole genome sequencing workflow that requires 10- to 100-fold less sequencing coverage versus other error correction techniques. These researchers conclude that these key features make ppmSeq well suited for clinical applications where high accuracy is required for mutation identification, such as tumor informed and tumor agnostic MRD detection.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
